Diarrea aguda: Bibliografía

  • Creado el:
  • / Autoria: Guía PRIOAM
  • / Vistas: 2017 Vistas

Bibliografía.

  1. Manatsathit S, Dupont HL, Farthing M, et al. Guideline for the management of acute diarrhea in adults. J Gastroenterol Hepatol. 2002;17Suppl:S54-71.
  2. Thielman N M, Guerrant R. L. Acute Infectious Diarrhea. N Engl J Med 2004; 350: 38-74.
  3. Bruzzese E, Lo Vecchio A, Guarino A. Hospital management of children with acute gastroenteritis. Curr Opin Gastroenterol. 2013 Jan;29(1):23-30. Doi 10.1097/MOG.0b013e32835a352f.
  4. Debast SB, Bauer MP, Kuijper EJ, European Society of Clinical M, Infectious D. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile Clin Microbiol Infect. 2014;20 Suppl 2:1-26.
  5. Mary Y. HU, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V, Xu H, Leffler DA, Kelly CP. Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection. Gastroenterology 2009;136:1206 –1214
  6. Cobo J, Merino E, Martínez C, Cózar-Llistó A, Shaw E,
 Marrodán T, Calbo E, Bereciartúa E, Sánchez-Muñoz LA, Salavert M,
 Pérez-Rodríguez MT, García-Rosado D, Bravo-Ferrer JM, Gálvez-Acebal J, Henríquez-Camacho C, Cuquet J, Pino-Calm B, Torres L, Sánchez-Porto A, Fernández-Félix BM for the Nosocomial Infection Study Group. Prediction of recurrent clostridium difficile infection at the bedside: the GEIH-CDI score. Int J of Antimicrobial Agents 2018;51;393–398.
  7. CP Kelly. Can we identify patients at high risk of recurrent Clostridium difficileinfection?. Clin Microbiol Infect 2012; 18 (Suppl. 6): 21–27
  8. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018 19;66:987-994.
  9. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478-98; quiz 99.
  10. Mushtaq A. New clinical recommendations for Clostridium difficile.Lancet Infect Dis. 2018;18:384
  11. H. Wilcox, D.N. Gerding, I.R. Poxton, C. Kelly, R. Nathan, T. Birch, O.A. Cornely, G. Rahav, E. Bouza, C. Lee, G. Jenkin, W. Jensen, Y.-S. Kim, J. Yoshida, L. Gabryelski, A. Pedley, K. Eves, R. Tipping, D. Guris, N. Kartsonis, and M.-B. Dorr, for the MODIFY I and MODIFY II Investigators*. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. NEJM 2017; 376: 305-317.
  12. Hemant Goyala, Abhilash Perisettic, M. Rubayat Rehmanc, and Umesh Singla. New and emerging therapies in treatment of Clostridium difficile infection. Eur J Gastroenterol Hepatol 2018; 30:589–597.
  13. Dale N. Gerding, Ciaran P. Kelly, Galia Rahav, Christine Lee, Erik R. Dubberke, Princy N. Kumar, Bruce Yacyshyn, Dina Kao, Karen Eves, Misoo C. Ellison, Mary E. Hanson, Dalya Guris, and Mary Beth Dorr. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Clinical Infectious Diseases 2018;XX(00):1–8.
  14. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficilein Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281-9.
  15. Yafet Mamo, Michael H. Woodworth, Tiffany Wang, Tanvi Dhere, and Colleen S. Kraft. Durability and long-term clinical outcomes of fecal microbiota transplant treatment in patients with recurrent Clostridium difficile CID 2018;66:1705–11.
  16. Rubio-Terrés, J. Cobo Reinoso, S. Grau Cerrato, J. Mensa Pueyo, M. Salavert Lletí, A. Toledo, P. Anguita, D. Rubio-Rodríguez, M. Watt, R. Gani. Economic assessment of fidaxomicin for the treatment
of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment
or renal impairment) in Spain. Eur J Clin Microbiol Infect Dis DOI 10.1007/s10096-015-2472-0.
  17. Phatharacharukul, C. Thongprayoon, W. Cheungpasitporn, P.J. Edmonds,P. Mahaparn, J. Bruminhent. The Risks of Incident and Recurrent Clostridium difficile- Associated Diarrhea in Chronic Kidney Disease and End-Stage Kidney Disease Patients: A Systematic Review and Meta-Analysis. Dig Dis Sci 2015;60:2913–2922.
  18. M. Mullane, O.A. Cornely, D.W. Crook, Y. Golan, T.J. Louie, M. A. Miller, M.A. Josephson, S.L. Gorbach. Renal Impairment and Clinical Outcomes of Clostridium difficile Infection in Two Randomized Trials. Am J Nephrol 2013;38:1–11.
  19. M. Mullane, M. A. Miller, K. Weiss, A. Lentnek, Y. Golan, P. S. Sears, Y-Kong Shue, T. J. Louie, and S. L. Gorbach. Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections. Clinical Infectious Diseases 2011;53:440–447.
  20. Guery, F. Menichetti, V. Anttila, N. Adomakoh, J. M. Aguado, K. Bisnauthsing, A. Georgopali, S. D. Goldenberg, A. Karas, G. Kazeem, C. Longshaw, J. A. Palacios-Fabrega, O. A. Cornely, M. J. G. T. Vehreschild, for the EXTEND Clinical Study Group*. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Published online December 19, 2017 http://dx.doi.org/10.1016/S1473-3099(17)30751-X.